PriceTargets.com logo

InMode - INMD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $32.80
  • Forecasted Upside: 88.94%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$17.36 As of 04/24/2024 01:00 AM ET
▼ -0.01 (-0.06%)

This chart shows the closing price for INMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New InMode Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INMD

Analyst Price Target is $32.80
▲ +88.94% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for InMode in the last 3 months. The average price target is $32.80, with a high forecast of $61.00 and a low forecast of $22.00. The average price target represents a 88.94% upside from the last price of $17.36.

This chart shows the closing price for INMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in InMode. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2024BarclaysLower TargetOverweight ➝ Overweight$34.00 ➝ $33.00Low
4/9/2024Needham & Company LLCReiterated RatingHoldLow
2/15/2024BarclaysBoost TargetOverweight ➝ Overweight$32.00 ➝ $34.00Low
2/14/2024UBS GroupBoost TargetNeutral ➝ Neutral$24.00 ➝ $26.00Low
1/18/2024BarclaysLower TargetOverweight ➝ Overweight$33.00 ➝ $32.00Low
1/4/2024BarclaysLower TargetOverweight ➝ Overweight$45.00 ➝ $33.00Low
12/7/2023Canaccord Genuity GroupReiterated RatingHold ➝ Hold$22.00Low
11/3/2023UBS GroupReiterated RatingBuy ➝ Neutral$52.00 ➝ $24.00N/A
10/13/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$55.00 ➝ $22.00Low
10/13/2023Canaccord Genuity GroupDowngradeBuy ➝ Hold$55.00 ➝ $22.00Low
8/1/2023BarclaysBoost TargetOverweight ➝ Overweight$47.00 ➝ $54.00Low
7/28/2023Canaccord Genuity GroupBoost TargetBuy$47.00 ➝ $55.00Low
7/28/2023Robert W. BairdBoost TargetOutperform$53.00 ➝ $61.00Low
5/4/2023BarclaysBoost Target$45.00 ➝ $47.00Low
3/28/2023UBS GroupInitiated CoverageBuy$40.00Low
2/17/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
2/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$60.00Low
2/15/2023BarclaysBoost TargetOverweight$44.00 ➝ $45.00Low
12/21/2022BarclaysInitiated CoverageOverweight$44.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageBuy$40.00Low
7/29/2022Needham & Company LLCBoost TargetBuy$58.00 ➝ $60.00Low
7/29/2022Robert W. BairdBoost Target$44.00 ➝ $53.00Low
7/13/2022Robert W. BairdLower Target$57.00 ➝ $44.00N/A
6/30/2022Canaccord Genuity GroupLower TargetBuy$50.00 ➝ $40.00Low
5/5/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$72.00 ➝ $50.00Low
5/3/2022Robert W. BairdLower Target$82.00 ➝ $57.00Medium
4/18/2022Needham & Company LLCReiterated RatingBuy$82.00Medium
2/11/2022Needham & Company LLCLower TargetBuy$103.00 ➝ $82.00High
10/27/2021Robert W. BairdBoost TargetOutperform$80.00 ➝ $96.00High
10/13/2021Robert W. BairdBoost TargetOutperform$62.00 ➝ $80.00High
10/13/2021BarclaysBoost TargetOverweight$60.00 ➝ $85.00High
10/12/2021Needham & Company LLCLower TargetBuy$103.00Low
7/29/2021Needham & Company LLCBoost TargetBuy$29.75 ➝ $32.25High
7/13/2021BarclaysBoost TargetOverweight$23.00 ➝ $30.00Low
7/12/2021Needham & Company LLCBoost TargetBuy$23.50 ➝ $29.75Medium
5/24/2021BarclaysInitiated CoverageOverweight$23.00Medium
5/18/2021Needham & Company LLCInitiated CoverageBuy$23.50Medium
5/6/2021Robert W. BairdBoost TargetOutperform$21.00 ➝ $26.00High
2/11/2021Robert W. BairdBoost TargetOutperform$14.50 ➝ $21.00Low
2/11/2021UBS GroupBoost TargetBuy$16.00 ➝ $21.00Low
10/14/2020UBS GroupBoost TargetBuy$10.75 ➝ $11.75High
10/13/2020Robert W. BairdBoost TargetOutperform$10.75 ➝ $13.75High
8/17/2020BarclaysBoost TargetOverweight$9.00 ➝ $9.50High
5/7/2020UBS GroupLower TargetBuy$11.50 ➝ $10.50Low
3/26/2020BarclaysLower TargetOverweight$12.00 ➝ $9.00Low
2/19/2020BarclaysBoost TargetOverweight$11.25 ➝ $12.00High
1/28/2020Robert W. BairdReiterated RatingOutperform$11.25 ➝ $13.75Medium
11/6/2019BarclaysBoost TargetOverweight$6.75 ➝ $11.25High
11/6/2019Robert W. BairdReiterated RatingOutperform$6.75 ➝ $11.25High
9/3/2019BarclaysInitiated CoverageOverweight$6.75High
9/3/2019Robert W. BairdInitiated CoverageOutperform$6.75High
9/3/2019UBS GroupInitiated CoverageBuy$7.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 8 very positive mentions
  • 10 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
10/28/2023
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 15 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 17 very positive mentions
  • 47 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 10 very positive mentions
  • 35 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 14 very positive mentions
  • 38 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 14 very positive mentions
  • 38 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

InMode logo
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Read More

Today's Range

Now: $17.36
Low: $17.16
High: $17.43

50 Day Range

MA: $20.57
Low: $17.14
High: $23.77

52 Week Range

Now: $17.36
Low: $16.96
High: $48.25

Volume

924,916 shs

Average Volume

1,582,236 shs

Market Capitalization

$1.46 billion

P/E Ratio

7.55

Dividend Yield

N/A

Beta

2.16

Frequently Asked Questions

What sell-side analysts currently cover shares of InMode?

The following Wall Street research analysts have issued stock ratings on InMode in the last year: Barclays PLC, Canaccord Genuity Group Inc., Needham & Company LLC, Robert W. Baird, TheStreet, and UBS Group AG.
View the latest analyst ratings for INMD.

What is the current price target for InMode?

5 Wall Street analysts have set twelve-month price targets for InMode in the last year. Their average twelve-month price target is $32.80, suggesting a possible upside of 88.9%. Robert W. Baird has the highest price target set, predicting INMD will reach $61.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $22.00 for InMode in the next year.
View the latest price targets for INMD.

What is the current consensus analyst rating for InMode?

InMode currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in INMD, but not buy more shares or sell existing shares.
View the latest ratings for INMD.

What other companies compete with InMode?

Other companies that are similar to InMode include Soleno Therapeutics, Natus Medical, BioLife Solutions, CONMED and AxoGen. Learn More about companies similar to InMode.

How do I contact InMode's investor relations team?

InMode's physical mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company's listed phone number is 972-4909-7470 and its investor relations email address is [email protected]. The official website for InMode is www.inmodemd.com. Learn More about contacing InMode investor relations.